Physician profile
Daniel P Petro
NPI 1649242710
$28,029.07
in general payments reported to CMS, 2019-2025
12 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $8,337 · 2021: $326 · 2022: $4,883 · 2023: $94.56 · 2024: $2,277 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,388 · Food and Beverage: $336 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,387.50 |
| Food and Beverage | $336.42 |
| Education | $111.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $20,356.70 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Blueprint Medicines Corporation | $3,960.00 | 2020 | |
| Dendreon Pharmaceuticals LLC | $1,635.22 | 2019 | |
| Jazz Pharmaceuticals INC. | $1,260.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $268.12 | 2020-2024 | Opdivo |
| Celgene Corporation | $267.76 | 2019-2025 | Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $113.50 | 2019 | |
| Beigene USA, INC. | $70.19 | 2021-2024 | Brukinsa |
| Genentech USA, INC. | $44.70 | 2023 | Tecentriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.46 | 2025 | |
| Beone Medicines USA, INC. | $18.45 | 2025 | Brukinsa |
| Lilly USA, LLC | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Petro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.